Occurrence of internal diseases in the premotor phase of Parkinson’s disease by analyzing a large database covering a whole population


The premotor phase of Parkinson’s disease (PD) precedes the appearance of motor symptoms by years. Many non-motor diseases have been associated with an increased risk of developing PD, but results of these studies are conflicting. The aim of this study was to investigate the occurrence of certain internal diseases (metabolic, circulatory, gastrointestinal) based on diagnosis codes, before the diagnosis of PD. There were 5209 patients included in the study who received diagnosis of PD at least in 2 years and we analyzed data retrospectively between 2004 and 2016. Out of metabolic diseases dyslipidemia (41%) and diabetes mellitus (32%), out of circulatory diseases hypertension (89%) and ischemic heart disease (51%) and out of gastrointestinal diseases gastroesophageal reflux disease (51%) and gallstones (25%) were the first two most common disorders in the examined PD patients. This is the first study in Hungary which analyzed PD in a large database in the context of internal diseases, and raised the possibility of a link between dyslipidemias, diabetes mellitus, hypertension, ischemic heart disease, gastooesophagial reflux, gallstones and PD.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Mahlknecht P, Seppi K, Poewe W. The Concept of prodromal Parkinson’s disease. J Parkinsons Dis. 2015;5(4):681–97.

  • 2. Hilker R, Schweitzer K, Coburger S, Ghaemi M, Weisenbach S, Jacobs AH, et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol. 2005 Mar;62(3):378–82.

  • 3. Csoti I, Jost WH, Reichmann H. Parkinson’s disease between internal medicine and neurology. J Neural Transm. 2016 Jan;123(1):3–17.

  • 4. De Pablo-Fernandez E, Goldacre R, Pakpoor J, Noyce AJ, Warner TT. Association between diabetes and subsequent Parkinson disease: A record-linkage cohort study. Neurology. 2018 Jul;91(2):e139–42.

  • 5. Hu G, Antikainen R, Jousilahti P, Kivipelto M, Tuomilehto J. Total cholesterol and the risk of Parkinson disease. Neurology. 2008 May;70(21):1972–9.

  • 6. Ajtay A, Oberfrank F, Bereczki D. [Applicability of hospital reports submitted for reimbursement purposes for epidemiological studies based on the example of ischemic cerebrovascular diseases]. Orv Hetil. 2015 Sep;156(38):1540–6.

  • 7. Szatmari S Jr, Ajtay A, Balint M, Takats A, Oberfrank F, Bereczki D. Linking individual patient data to estimate incidence and prevalence of Parkinson’s disease by comparing reports of neurological services and pharmacy prescription refills at a nationwide level. Front Neurol. 2019;10:640.

  • 8. Szigethy E, Szeles G, Horvath A, Hidvegi T, Jermendy G, Paragh G, et al. Epidemiology of the metabolic syndrome in Hungary. Public Health. 2012 Feb;126(2):143–9.

  • 9. Notkola IL, Sulkava R, Pekkanen J, Erkinjuntti T, Ehnholm C, Kivinen P, et al. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer’s disease. Neuroepidemiology. 1998;17(1):14–20.

  • 10. Kivipelto M, Helkala E-L, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, et al. Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med. 2002 Aug;137(3):149–55.

  • 11. Paul R, Choudhury A, Kumar S, Giri A, Sandhir R, Borah A. Cholesterol contributes to dopamine-neuronal loss in MPTP mouse model of Parkinson’s disease: Involvement of mitochondrial dysfunctions and oxidative stress. PLoS One. 2017;12(2):e0171285.

  • 12. Paul R, Choudhury A, Borah A. Cholesterol - A putative endogenous contributor towards Parkinson’s disease. Neurochem Int. 2015 Nov;90:125–33.

  • 13. Vikdahl M, Backman L, Johansson I, Forsgren L, Haglin L. Cardiovascular risk factors and the risk of Parkinson’s disease. Eur J Clin Nutr. 2015 Jun;69(6):729–33.

  • 14. Huang X, Abbott RD, Petrovitch H, Mailman RB, Ross GW. Low LDL cholesterol and increased risk of Parkinson’s disease: prospective results from Honolulu-Asia Aging Study. Mov Disord. 2008 May;23(7):1013–8.

  • 15. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol. 2006 Jan;5(1):64–74.

  • 16. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology. 1999 Dec;53(9):1937–42.

  • 17. Friederich M, Hansell P, Palm F. Diabetes, oxidative stress, nitric oxide and mitochondria function. Curr Diabetes Rev. 2009 May;5(2):120–44.

  • 18. Henchcliffe C, Beal MF. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol. 2008 Nov;4(11):600–9.

  • 19. Biosa A, Outeiro TF, Bubacco L, Bisaglia M. Diabetes mellitus as a risk factor for Parkinson’s disease: a molecular point of view. Mol Neurobiol. 2018 Nov;55(11):8754–63.

  • 20. Pagano G, Polychronis S, Wilson H, Giordano B, Ferrara N, Niccolini F, et al. Diabetes mellitus and Parkinson disease. Neurology. 2018 May;90(19):e1654–62.

  • 21. Schernhammer E, Hansen J, Rugbjerg K, Wermuth L, Ritz B. Diabetes and the risk of developing Parkinson’s disease in Denmark. Diabetes Care. 2011 May;34(5):1102–8.

  • 22. Hu G, Jousilahti P, Bidel S, Antikainen R, Tuomilehto J. Type 2 diabetes and the risk of Parkinson’s disease. Diabetes Care. 2007 Apr;30(4):842–7.

  • 23. Yang Y-W, Hsieh T-F, Li C-I, Liu C-S, Lin W-Y, Chiang J-H, et al. Increased risk of Parkinson disease with diabetes mellitus in a population-based study. Medicine (Baltimore). 2017 Jan;96(3):e5921.

  • 24. Marko-Kucsera M, Vecsei L, Paulik E. Association of cardiovascular risk factors and Parkinson’s disease - case-control study in South East Hungary. Ideggyogy Sz. 2018 Jan;71(1–2):57–62.

  • 25. Lu L, Fu D-L, Li H-Q, Liu A-J, Li J-H, Zheng G-Q. Diabetes and risk of Parkinson’s disease: an updated meta-analysis of case-control studies. PLoS One. 2014;9(1):e85781.

  • 26. Jain S. Multi-organ autonomic dysfunction in Parkinson disease. Parkinsonism Relat Disord. 2011 Feb;17(2):77–83.

  • 27. Mendoza-Velasquez JJ, Flores-Vazquez JF, Barron-Velazquez E, Sosa-Ortiz AL, Illigens B-MW, Siepmann T. Autonomic dysfunction in alpha-synucleinopathies. Front Neurol. 2019;10:363.

  • 28. Fanciulli A, Gobel G, Ndayisaba JP, Granata R, Duerr S, Strano S, et al. Supine hypertension in Parkinson’s disease and multiple system atrophy. Clin Auton Res. 2016 Apr;26(2):97–105.

  • 29. Umehara T, Matsuno H, Toyoda C, Oka H. Clinical characteristics of supine hypertension in de novo Parkinson disease. Clin Auton Res. 2016 Feb;26(1):15–21.

  • 30. Qiu C, Hu G, Kivipelto M, Laatikainen T, Antikainen R, Fratiglioni L, et al. Association of blood pressure and hyper-tension with the risk of Parkinson disease: the National FINRISK Study. Hypertens (Dallas, Tex 1979). 2011 Jun;57(6):1094–100.

  • 31. Jain S, Ton TG, Perera S, Zheng Y, Stein PK, Thacker E, et al. Cardiovascular physiology in premotor Parkinson’s disease: a neuroepidemiologic study. Mov Disord. 2012 Jul;27(8):988–95.

  • 32. Li Q, Wang C, Tang H, Chen S, Ma J. Stroke and coronary artery disease are associated with Parkinson’s disease. Can J Neurol Sci. 2018 Sep;45(5):559–65.

  • 33. Simon KC, Chen H, Schwarzschild M, Ascherio A. Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology. 2007 Oct;69(17):1688–95.

  • 34. Miyake Y, Tanaka K, Fukushima W, Sasaki S, Kiyohara C, Tsuboi Y, et al. Case-control study of risk of Parkinson’s disease in relation to hypertension, hypercholesterolemia, and diabetes in Japan. J Neurol Sci. 2010 Jun;293(1–2):82–6.

  • 35. Scorza FA, Fiorini AC, Scorza CA, Finsterer J. Cardiac abnormalities in Parkinson’s disease and parkinsonism. J Clin Neurosci Off J Neurosurg Soc Australas. 2018 Jul; 53:1–5.

  • 36. Ronkainen J, Agreus L. Epidemiology of reflux symptoms and GORD. Best Pract Res Clin Gastroenterol. 2013 Jun;27(3):325–37.

  • 37. Aerts R, Penninckx F. The burden of gallstone disease in Europe. Aliment Pharmacol Ther. 2003 Nov;18 Suppl 3:49–53.

  • 38. Cersosimo MG, Benarroch EE. Neural control of the gastrointestinal tract: implications for Parkinson disease. Mov Disord. 2008 Jun;23(8):1065–75.

  • 39. Maeda T, Nagata K, Satoh Y, Yamazaki T, Takano D. High prevalence of gastroesophageal reflux disease in Parkinson’s disease: a questionnaire-based study. Parkinsons Dis. 2013;2013:742128.

  • 40. Makaroff L, Gunn A, Gervasoni C, Richy F. Gastrointestinal disorders in Parkinson’s disease: prevalence and health outcomes in a US claims database. J Parkinsons Dis. 2011;1(1):65–74.

  • 41. Modaine P, Levy S, Masmoudi K, Capron D, Votte A, Josse C, et al. Parkinson’s disease: a new risk factor for gallstone disease? Vol. 23, Journal of hepatology. Netherlands; 1995. p. 484.

  • 42. Maki T, Sonoda Y, Sugita K. [Gallstone and Parkinson’s disease--ultrasound echography study]. Rinsho Shinkeigaku. 1990 Jul;30(7):728–30.

  • 43. Gerstenbrand F, Poewe W. Dopaminergic-peptidergic interactions in extrapyramidal disorders: a review of the clinical evidence. Adv Neurol. 1987;45:67–73.


Journal + Issues